RxDoctor Payments Data

Andrew Kinchen, MD

Family Medicine · Paducah, KYNPI 1124554951

Payments from drug & device makers

$7,649in general payments, 2019–2025

Across 489 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$923
  • Lilly USA, LLC$559
  • Boehringer Ingelheim$470
  • AstraZeneca$425
  • Amgen$417
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$7,649100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,649 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$318,970
Medicare patients
491
Services billed
10,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$63,176
EliquisApixaban49$38,902
FarxigaDapagliflozin Propanediol45$36,027
JardianceEmpagliflozin32$35,835
XareltoRivaroxaban34$23,469
MyrbetriqMirabegron14$15,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,487
Repatha SureclickEvolocumab11$12,372
LinzessLinaclotide19$10,797
KerendiaFinerenone14$10,012
Repatha SyringeEvolocumab12$6,603
Albuterol Sulfate HfaAlbuterol Sulfate38$1,279
Duloxetine Hcl27$1,250
Bupropion XlBupropion Hcl46$1,165
Levothyroxine Sodium93$1,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$923$63,17666 claims
PfizerEliquis$191$38,90249 claims
AstraZenecaFarxiga$425$36,02745 claims
Boehringer IngelheimJardiance$470$35,83532 claims
Johnson & JohnsonXarelto$140$23,46934 claims
Astellas Pharma US IncMyrbetriq$212$15,94414 claims
GSKTrelegy Ellipta$19$14,48715 claims
AbbVieLinzess$1,388$10,79719 claims
BayerKerendia$191$10,01214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →